缬沙坦联合金水宝治疗慢性肾炎蛋白尿临床研究

[目的]探讨缬沙坦联合金水宝治疗慢性肾炎蛋白尿的临床疗效。[方法]将2007年1月至2010年2月本院收治的90例慢性肾炎蛋白尿患者按就诊顺序随机分成治疗组和对照组各45例。对照组在基础综合治疗后加用卡托普利片,治疗组加用缬沙坦和金水宝片。两组均连续用药12周后进行疗效评价。[结果]治疗组与对照组相比,治疗后肌酐及尿蛋白定量明显下降,临床症状体征好转,差异均具有统计学意义(P0.01)。治疗组总缓解率为88.89%,与对照组相比差异有统计学意义(P0.05)。[结论]缬沙坦联合金水宝治疗慢性肾炎蛋白尿具有疗效显著、副反应小、安全可靠等优点,值得临床推广使用。

Clinical Study in Treatment of Chronic Glomerulonephritis with Valsartan and Jinshuibao

[Objective] Clinical efficacy of valsartan, jinshuibao treatment of chronic glomemlonephritis. [Methods] 90 patients with chronic glomerulonephritis in the order of 1：1 according to treatment were randomly divided into treatment group and control group of 45 patients, two groups of patients in gender, age, disease duration, blood urea nitrogen, creatinine, urine protein had no statistically significant difference （P 〉0.05）. All patients were given low-salt, high-calorie, low phosphorus, low-fat, high protein diet, controlling blood pressure, correcting water, electrolyte and acid-base balance, infection control, anticoagulation therapy, and other comprehensive measures to control group with Captopril Tablets 12.5-25 mg, bid, po. Treatment group received valsartan 80 mg, qd, morning, Burton clothing, Jinshuibao 3, tid, po. Both groups after 12 weeks of continuous treatment had efficacy evaluation. [Results]The treatment group compared with the control group after treatment, creatinine and urinary protein significantly decreased, the clinical symptoms and signs improved, the differences were statistically sigrfificant（P〈0.01）. Treatment group, overall response rate was 88.9%（40/45） and control group 71.1%（32/45）, the difference was statistically significant（P〈0.05）. [Conclusion ] Jinshuibao valsartan combined treatment of chronic glomemlonephritis has a significant effect, httle side effects, safe and reliable, worthy of clinical use.